![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Approves Treatment for Thrombocytopenia
FDA Approves Treatment for Thrombocytopenia
![FDA_Logo_Blue_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Blue_2016.gif?t=1578316591&width=430)
The FDA approved AkaRx’s Doptelet (avatrombopag) for treating low blood platelet count in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.
The approval was based on two trials involving 435 patients with severe thrombocytopenia and chronic liver disease who were to undergo a procedure that would normally require blood platelet transfusion.
The trials showed that both dosage levels of Doptelet led to a higher proportion of patients with increased platelet counts that did not require transfusion or post-procedure therapy on the day of the procedure and up to seven days afterwards.
Upcoming Events
-
21Oct